A 12-week, Randomized, Parallel-group, Phase III Study Comparing the Efficacy of Once-daily Budesonide/formoterol Turbuhaler (160/4.5 μg/d) with Twice-daily Budesonide (400 μg/d) During the Step-down Period in Well-controlled Asthma
OBJECTIVES: Budesonide/formoterol fumarate (BUD/FF) is recommended in the stepwise management of uncontrolled asthma, butdata on a once-daily dose of this medication in a step-down period are lacking.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:OBJECTIVES: Budesonide/formoterol fumarate (BUD/FF) is recommended in the stepwise management of uncontrolled asthma, butdata on a once-daily dose of this medication in a step-down period are lacking.
📊
Key Findings & Data:We aimed to compare BUD/FF and BUD in terms of thechanges in asthma control scores and lung functions.MATERIAL AND METHODS: This 12-week, randomized, parallel-group, single-center, open-label study was conducted in well-con-trolled asthmatic patients receiving twice-daily BUD/FF (160/4.5 μg 2 inhalations) randomized into once-daily BUD/FF (160/4.5 μg 1inhalation) or twice-daily BUD (200 μg 2 inhalations).RESULTS: At week 12, the medians of Asthma Control Test (ACT) were 23 (interquartile range [IQR]: 22-24) in the BUD/FF group and 23(IQR: 22-24.5) in the BUD group, while the medians of Asthma Control Questionnaire (ACQ) were 0.43 (IQR: 0.29-0.82) in the BUD/FFgroup and 0.57 (IQR: 0.43-0.93) in the BUD group.
💡
Conclusion & Impact:PEF in theBUD/FF group and FEV 1 in both treatments significantly decreased from baseline to week 12.CONCLUSION: Compared to twice-daily BUD, once-daily BUD/FF provides equivalent asthma control scores and lung function duringthe step-down period after switching from twice-daily doses of BUD/FF in well-controlled asthma.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
OBJECTIVES: Budesonide/formoterol fumarate (BUD/FF) is recommended in the stepwise management of uncontrolled asthma, butdata on a once-daily dose of this medication in a step-down period are lacking. We aimed to compare BUD/FF and BUD in terms of thechanges in asthma control scores and lung functions.MATERIAL AND METHODS: This 12-week, randomized, parallel-group, single-center, open-label study was conducted in well-con-trolled asthmatic patients receiving twice-daily BUD/FF (160/4.5 μg 2 inhalations) randomized into once-daily BUD/FF (160/4.5 μg 1inhalation) or twice-daily BUD (200 μg 2 inhalations).RESULTS: At week 12, the medians of Asthma Control Test (ACT) were 23 (interquartile range [IQR]: 22-24) in the BUD/FF group and 23(IQR: 22-24.5) in the BUD group, while the medians of Asthma Control Questionnaire (ACQ) were 0.43 (IQR: 0.29-0.82) in the BUD/FFgroup and 0.57 (IQR: 0.43-0.93) in the BUD group. No statistically significant difference was observed in either ACT (p=0.673) or ACQ(p=0.295) between the treatments. The ACT scores significantly decreased from baseline to week 12 in both treatments. Peak expiratoryflow (PEF) and forced expiratory volume in 1 second (FEV 1 ) also had no statistically significant differences between treatments. PEF in theBUD/FF group and FEV 1 in both treatments significantly decreased from baseline to week 12.CONCLUSION: Compared to twice-daily BUD, once-daily BUD/FF provides equivalent asthma control scores and lung function duringthe step-down period after switching from twice-daily doses of BUD/FF in well-controlled asthma.
🔖
Cite This Article
NAKWAN, N., TAMSAWAI, T., TAPTAWEE, P., USAHA, S., PERKLEANG, T. (2022). A 12-week, Randomized, Parallel-group, Phase III Study Comparing the Efficacy of Once-daily Budesonide/formoterol Turbuhaler (160/4.5 μg/d) with Twice-daily Budesonide (400 μg/d) During the Step-down Period in Well-controlled Asthma. Turkish Thoracic Journal, Cilt: 19 - Sayı: 2, 66–72. https://ajindex.com/articles/618121
Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol 2015
[CrossRef] Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014
[CrossRef] British Thoracic Society, Scottish Intercollegiate Guidelines Net- work. British guideline on the management of asthma. Thorax 2014
Global Initiative for Asthma (GINA), Global Strategy for Asth- ma Management and Prevention, Updated 2015. Available at: http://www.ginasthma.org, 2015 (accessed December 1.2015). Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998
[CrossRef] Brozek JL, Kraft M, Krishnan JA, et al. Long-acting β2-agonist step-off in patients with controlled asthma. Arch Intern Med 2012
[CrossRef] Bateman ED, Harrison TW, Quirce S, et al. Overall asthma con- trol achieved with budesonide/formoterol maintenance and re- liever therapy for patients on different treatment steps. Respir Res 2011
[CrossRef] O’Byrne PM, Naya IP, Kallen A, et al. Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2- agonists in achieving asthma control. Chest 2008
[CrossRef] Masoli M, Williams M, Weatherall M, et al. The 24 h duration of bronchodilator action of the budesonide/formoterol combina- tion inhaler. Respir Med 2006
[CrossRef] Kuna P, Creemers JP, Vondra V, et al. Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/ formoterol and once-daily budesonide in adults with mild to moderate asthma. Respir Med 2006
[CrossRef] Buhl R, Creemers JP, Vondra V, et al. Once-daily budesonide/ formoterol in single inhaler in adults with moderate persistent asthma. Respir Med 2003
[CrossRef] Lalloo UG, Malolepszy J, Kozma D, et al. Symbicort® (budesonide and formoterol in a single inhaler) is more effec- tive than increasing the dose of inhaled corticosteroids in mild asthma. Am J Respir Crit Care Med 2001
A863. Standardization of spirometry, 1994 update. American Tho- racic Society. Am J Respir Crit Care Med 1995
[CrossRef] Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Al- lergy Clin Immunol 2004
[CrossRef] Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: re- liability, validity, and re